

ASX Release

Oventus Medical Signs Strategic Collaboration Agreement with 1300 SMILES Ltd

Key Points:

- **Strategic Collaboration paves way for O2Vent T™ to be sold through 1300SMILES Ltd dental group**
- **Major milestone for Australian expansion plans - allows Oventus to accelerate market penetration and geographical coverage and facilitates the expansion of dental sleep medicine services into the 1300SMILES Ltd network**
- **1300SMILES Ltd owns and operates full-service dental facilities in over 20 sites in major population centres in Queensland, NSW and South Australia**

Brisbane, Australia 28th October 2016: Oventus Medical Ltd is proud to announce it has entered into a collaboration agreement with 1300SMILES Ltd.

This collaboration allows 1300SMILES's dentists to provide treatment for snoring and obstructive sleep apnoea (OSA) sufferers with the use of Oventus products.

Managing Director of 1300SMILES, Dr Daryl Holmes, said "We are very excited about this new arrangement, which allows our Dentists and Practices to provide this innovative, life-changing product and service to our patients. This increases the scope and range of services we offer and hence revenue streams and profitability for our group."

Incredibly, more than 800,000 Australians suffer from obstructive sleep apnoea (OSA) ¹, whilst the global sleep disordered breathing market is estimated to be worth \$50 billion annually.

The device, which was created by Brisbane dentist Dr Chris Hart, who founded Oventus and is the company's Clinical Director, is indicated for use during sleep to aid in the treatment of snoring and OSA.

A clinical study completed earlier this year showed the company's first generation product the O₂VENT Mono™ is successful in treating OSA and that snoring was either eliminated or significantly reduced in 100 per cent of patients². The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep.

Oventus Managing Director and Chief Executive Officer, Neil Anderson said "We are delighted to be working with a professional and well established dental corporate partner, and look forward to a mutually beneficial collaboration. This collaboration provides us with

direct access to the 1300SMILES group of clinicians and will ultimately allow more patients with obstructive sleep apnoea to be brought into care.”

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Oventus Clinical Trial Report. Data on file.*

-ENDS-

For more information please contact:

Dr Mel Bridges, Chairman: M: 0413 051 600 (+61413051600)

Kyahn Williamson, WE Buchan: P: 03 8866 1214 or kwilliamson@buchanwe.com.au

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*